Products
Addressing important unmet medical needs
Our products
Camurus’ products are based on our proprietary FluidCrystal® technology and are designed to address important unmet medical needs, with the potential to make a significant difference in the daily life of patients by improving treatment outcomes, quality of life, and long-term recovery.
opioid dependence
Buvidal® prolonged-release solution for injection
Buvidal buprenorphine injection depot is indicated for the treatment of opioid dependence within a framework of medical, social and psychological treatment, and intended for use in adults and adolescents aged 16 years or over.
Buvidal is based on Camurus' proprietary FluidCrystal injection depot technology and is intended for weekly or monthly administration by healthcare professionals.
More information on buvidal.com (for healthcare professionals)
opioid USE DISORDER
Brixadi® (buprenorphine) extended-release for subcutaneous use
Brixadi (buprenorphine) extended-release injection for subcutaneous use is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine. Brixadi should be used as part of a complete treatment plan that includes counselling and psychosocial support.
Brixadi is the US trademark for Camurus’ product Buvidal. The product rights to Brixadi in North America are licensed to Braeburn by Camurus.
More information on Brixadi (for US healthcare professionals)
ACROMEGALY
Oczyesa® prolonged-release solution for injection
Oczyesa is a long-acting subcutaneous depot of octreotide indicated for maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogs.
Oczyesa is based on Camurus' proprietary FluidCrystal injection depot technology and is intended for monthly self-administration using an autoinjector pen.